Regina Baity, NP
Primary Care · Whitsett, NCNPI 1891123667
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 146 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 27 manufacturers reported payments, led by Novo Nordisk at 32.9% of the total.
Across 146 payments — averaging $16.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$784
- Lilly USA, LLC$369
- AstraZeneca$200
- AbbVie$195
- Pfizer$137
- Johnson & Johnson$86
- plus $612 from 21 others
What the payments were for
- Food & beverage$2,36999%
- Education$151%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 54 | $784 |
| Lilly USA, LLC | 21 | $369 |
| AstraZeneca | 10 | $200 |
| AbbVie | 11 | $195 |
| Pfizer | 8 | $137 |
| Johnson & Johnson | 6 | $86 |
| Exact Sciences | 5 | $78 |
| Amgen | 5 | $70 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $54 |
| Otsuka America Pharmaceutical, Inc. | 2 | $43 |
| Mylan Specialty L.p. | 2 | $37 |
| Vanda Pharmaceuticals Inc. | 1 | $31 |
| Alkermes, Inc. | 2 | $31 |
| Idorsia Pharmaceuticals US Inc | 2 | $30 |
| GSK | 2 | $29 |
| Dexcom, Inc. | 1 | $25 |
| Abbott | 1 | $24 |
| Aimmune Therapeutics, Inc. | 1 | $20 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
| Dynavax Technologies Corporation | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| Bayer | 1 | $15 |
| Verona Pharma, Inc. | 1 | $15 |
| Viatris Specialty LLC | 1 | $15 |
| Vertical Pharmaceuticals, LLC | 1 | $14 |
| Azurity Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Wegovy$122
How this compares
$2,384 in reported general payments places this provider in the 80th percentile of 236 primary care providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 42 | $59,492 |
| MounjaroTirzepatide | 31 | $49,125 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 51 | $47,940 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 12 | $44,071 |
| JanuviaSitagliptin Phosphate | 27 | $35,154 |
| EliquisApixaban | 33 | $34,590 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 24 | $19,384 |
| MyrbetriqMirabegron | 22 | $13,095 |
| LinzessLinaclotide | 19 | $11,457 |
| BelsomraSuvorexant | 14 | $5,990 |
| ConcertaMethylphenidate Hcl | 13 | $5,504 |
| SymbicortBudesonide/Formoterol Fumarate | 15 | $4,691 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 28 | $4,255 |
| Atorvastatin Calcium | 364 | $4,017 |
| Omeprazole | 192 | $3,869 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $784 | $59,49242 claims |
| Lilly USA, LLCMounjaro | $369 | $49,12531 claims |
| GSKTrelegy Ellipta | $29 | $47,94051 claims |
| PfizerEliquis | $137 | $34,59033 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $200 | $24,07539 claims |
| AbbVieLinzess, Synthroid | $195 | $14,08142 claims |
| Johnson & JohnsonConcerta | $86 | $5,50413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 236 primary care providers in North Carolina.
Other primary care in Whitsett
- Katherine ClarkWhitsett$2K
- Jessica AllynRaleigh$21K
- Jennifer RogersWinston Salem$17K
- Elizabeth WaltersChapel Hill$14K
- Ragan JohnsonChapel Hill$13K
- Kirkland DickeyPine Hall$11K
- Kimberly WeaverHickory$9K
- Amanda StoneWilmington$9K
- Elizabeth WalshGreensboro$7K
- Mark HollingsworthWilmington$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.